OverviewSuggest Edit

Dova Pharmaceuticals is a clinical-stage pharmaceutical company focused on acquiring, developing, and marketing treatments for thrombocytopenia, a disorder characterized by a low blood platelet count. The Company's major drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist.

Dova has recently completed two identically designed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease, or CLD, undergoing non-emergent minimally to moderately invasive medical procedures.

TypePublic
Founded2016
HQDurham, US
Websitedova.com
Employee Ratings0

Latest Updates

Employees (est.) (Jul 2017)7
Job Openings1
Share Price (Mar 2019)$8.9 (+3%)

Key People/Management at Dova Pharmaceuticals

Alex Sapir

Alex Sapir

President & CEO
Mark Hahn

Mark Hahn

CFO
Kevin Laliberte

Kevin Laliberte

Senior Vice President, Product Development
Caroline Diaz

Caroline Diaz

Director, Regulatory Affairs
Lee Allen

Lee Allen

Chief Medical Officer
Show more

Dova Pharmaceuticals Office Locations

Dova Pharmaceuticals has an office in Durham
Durham, US (HQ)
240 Leigh Farm Rd #245
Show all (1)
Report incorrect company information

Dova Pharmaceuticals Financials and Metrics

Dova Pharmaceuticals Revenue

USD

Net income (FY, 2016)

(27.2m)

EBIT (FY, 2016)

(27.0m)

Market capitalization (15-Mar-2019)

252.3m

Closing stock price (15-Mar-2019)

8.9

Cash (31-Dec-2016)

28.7m

EV

237.3m
Dova Pharmaceuticals's current market capitalization is $252.3 m.
USDFY, 2016

General and administrative expense

1.2m

R&D expense

25.8m

Operating expense total

27.0m

EBIT

(27.0m)
USDFY, 2016

Cash

28.7m

Current Assets

28.7m

Total Assets

28.7m

Accounts Payable

157.0k
USDFY, 2016

Net Income

(27.2m)

Accounts Payable

157.0k

Cash From Operating Activities

(987.0k)

Cash From Financing Activities

29.7m
USDY, 2016

EV/EBIT

-8.8 x

EV/CFO

-240.4 x

Debt/Equity

2 x

Debt/Assets

0.5 x

Financial Leverage

4.2 x
Show all financial metrics

Dova Pharmaceuticals Operating Metrics

Mar, 2017Jun, 2017

Patents (Foreign)

24

Patents Licensed

43

Patents Pending (Foreign)

2

Phase III Trials Products

1
Show all operating metrics
Report incorrect company information

Dova Pharmaceuticals News and Updates

Dova Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

DURHAM, N.C., March 05, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at …

Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

DOPTELET® (avatrombopag) approved May 21, 2018 and launched June 4, 2018

Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019

DURHAM, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, March 5, 2019 at 9:00 a.m. ET to discuss fourth quarter and full year 2018 financial results and recent operational highlights. A question-and-answer session will follo…

Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 3:00 p.m.…

Dova Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announced that on December 19, 2018, the Compensation Commi…

Dova Pharmaceuticals Announces Management Changes

Dr. David Zaccardelli appointed President and Chief Executive Officer
Show more
Report incorrect company information

Dova Pharmaceuticals Frequently Asked Questions

  • When was Dova Pharmaceuticals founded?

    Dova Pharmaceuticals was founded in 2016.

  • Who are Dova Pharmaceuticals key executives?

    Dova Pharmaceuticals's key executives are Alex Sapir, Mark Hahn and Kevin Laliberte.

  • How many employees does Dova Pharmaceuticals have?

    Dova Pharmaceuticals has 7 employees.

  • Who are Dova Pharmaceuticals competitors?

    Competitors of Dova Pharmaceuticals include Vitality Biopharma, Opiant Pharmaceuticals and IntelGenx.

  • Where is Dova Pharmaceuticals headquarters?

    Dova Pharmaceuticals headquarters is located at 240 Leigh Farm Rd #245, Durham.

  • Where are Dova Pharmaceuticals offices?

    Dova Pharmaceuticals has an office in Durham.

  • How many offices does Dova Pharmaceuticals have?

    Dova Pharmaceuticals has 1 office.